CN102917730A - 修饰的脑膜炎球菌fHBP多肽 - Google Patents

修饰的脑膜炎球菌fHBP多肽 Download PDF

Info

Publication number
CN102917730A
CN102917730A CN201080060450XA CN201080060450A CN102917730A CN 102917730 A CN102917730 A CN 102917730A CN 201080060450X A CN201080060450X A CN 201080060450XA CN 201080060450 A CN201080060450 A CN 201080060450A CN 102917730 A CN102917730 A CN 102917730A
Authority
CN
China
Prior art keywords
seq
polypeptide
sequence
amino acid
fhbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080060450XA
Other languages
English (en)
Chinese (zh)
Inventor
L·班西
F·坎蒂尼
S·德拉戈内蒂
M·A·简蒂莱
D·维吉
M·斯卡塞利
M·皮萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102917730A publication Critical patent/CN102917730A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080060450XA 2009-10-27 2010-10-27 修饰的脑膜炎球菌fHBP多肽 Pending CN102917730A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27997709P 2009-10-27 2009-10-27
US61/279,977 2009-10-27
PCT/IB2010/054865 WO2011051893A1 (en) 2009-10-27 2010-10-27 Modified meningococcal fhbp polypeptides

Publications (1)

Publication Number Publication Date
CN102917730A true CN102917730A (zh) 2013-02-06

Family

ID=43431124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080060450XA Pending CN102917730A (zh) 2009-10-27 2010-10-27 修饰的脑膜炎球菌fHBP多肽

Country Status (9)

Country Link
US (2) US20130022633A1 (enExample)
EP (1) EP2493499A1 (enExample)
JP (2) JP5960055B2 (enExample)
CN (1) CN102917730A (enExample)
AU (1) AU2010310985B2 (enExample)
BR (1) BR112012010531A2 (enExample)
CA (1) CA2779816A1 (enExample)
MX (1) MX2012004850A (enExample)
WO (1) WO2011051893A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431167A (zh) * 2013-08-02 2016-03-23 奥克兰儿童医院及研究中心 非天然发生因子h结合蛋白(fhbp)及其使用方法
CN106795208A (zh) * 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
CN112851768A (zh) * 2014-07-23 2021-05-28 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US11147866B2 (en) 2016-09-02 2021-10-19 Sanofi Pasteur Inc. Neisseria meningitidis vaccine
CN120241991A (zh) * 2025-06-05 2025-07-04 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体
US12485164B2 (en) 2014-07-17 2025-12-02 Glaxosmithkline Biologicals Sa Meningococcus vaccines

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
BR112012022669A2 (pt) * 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
SI3831406T1 (sl) 2010-08-23 2024-08-30 Wyeth Llc Stabilne formulacije antigenov neisseria meningitidis RLP2086
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2861247B1 (en) * 2012-06-14 2020-12-09 GlaxoSmithKline Biologicals SA Vaccines for serogroup x meningococcus
EP2877492A1 (en) 2012-07-27 2015-06-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
EP3400960A1 (en) * 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
BR112016004463A2 (pt) 2013-09-08 2017-10-17 Pfizer composições de neisseria meningitidis e métodos das mesmas
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
US10232029B2 (en) 2014-12-09 2019-03-19 Sanofi Pasteur Compositions comprising N. meningitidis proteins
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3312192B1 (en) * 2016-10-24 2023-02-22 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
WO2010046715A1 (en) * 2008-10-25 2010-04-29 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
AU8300282A (en) 1981-04-29 1982-11-04 Biogen N.V. Bacillus cloning vectors and method of expressing foreign dna
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
JPS6054685A (ja) 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2300854C (en) 1997-08-21 2011-04-05 Peter Andre Van Der Ley Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
BR9906927A (pt) 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
DK1126876T3 (da) 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
CA2383110A1 (en) 1999-09-24 2001-03-29 Veronique Henderickx Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP3701826B2 (ja) 1999-11-12 2005-10-05 株式会社村上開明堂 有色防曇鏡
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CN1433471A (zh) 1999-11-29 2003-07-30 启龙股份公司 85kgDa奈瑟球菌的抗原
CN102172398A (zh) 2000-01-17 2011-09-07 诺华疫苗和诊断有限公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
BR0107857A (pt) 2000-01-25 2002-10-29 Univ Queensland Proteìnas compreendendo regiões conservadas de antìgeno nhha de superfìcie de neisseria meningitidis
DE60144353D1 (de) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybride Expression Neisserscher Proteine
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
IL154853A0 (en) 2000-10-27 2003-10-31 Chiron Spa Nucleic acids and proteins from streptococcus groups a & b
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002330681C1 (en) 2001-07-26 2015-04-02 Glaxosmithkline Biologicals S.A. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CA2480389C (en) 2002-03-26 2012-10-09 Chiron Srl Modified saccharides having improved stability in water
AU2003260357B2 (en) 2002-08-02 2009-10-29 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE047780T2 (hu) 2002-10-11 2020-05-28 Glaxosmithkline Biologicals Sa Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
JP2006525330A (ja) 2003-04-16 2006-11-09 ワイエス・ホールディングス・コーポレーション 髄膜炎菌性疾患の予防および処置のための新規免疫原性組成物
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
AU2007263531B2 (en) * 2006-06-29 2012-03-15 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
CA2733943A1 (en) * 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007060548A2 (en) * 2005-11-25 2007-05-31 Novartis Vaccines And Diagnostics Srl Chimeric, hybrid and tandem polypeptides of meningococcal nmb1870
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
WO2010046715A1 (en) * 2008-10-25 2010-04-29 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELLEN MURPHY 等: "Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis", 《THE JOURNAL OF INFECTIOUS DISEASES》, vol. 200, no. 3, 1 August 2009 (2009-08-01), pages 379 - 389, XP002617504, DOI: 10.1086/600141 *
MURIEL C. SCHNEIDER 等: "Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates", 《NATURE》, 16 October 2009 (2009-10-16), pages 1 - 12 *
PETER T. BEERNINK 等: "Impaired Immunogenicity of a Meningococcal Factor H-Binding Protein Vaccine Engineered To Eliminate Factor H Binding", 《CLINICAL AND VACCINE IMMUNOLOGY》, vol. 17, no. 7, 31 July 2010 (2010-07-31), pages 1074 - 1078, XP009137321, DOI: 10.1128/CVI.00103-10 *
沈为群: "人Brg1蛋白Bromodomain结构域的溶液结构测定及其与乙酰化组蛋白的相互作用研究", 《中国博士学位论文全文数据库 基础科学辑》, no. 3, 15 September 2007 (2007-09-15) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431167A (zh) * 2013-08-02 2016-03-23 奥克兰儿童医院及研究中心 非天然发生因子h结合蛋白(fhbp)及其使用方法
CN106795208A (zh) * 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
US12485164B2 (en) 2014-07-17 2025-12-02 Glaxosmithkline Biologicals Sa Meningococcus vaccines
CN112851768A (zh) * 2014-07-23 2021-05-28 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US11147866B2 (en) 2016-09-02 2021-10-19 Sanofi Pasteur Inc. Neisseria meningitidis vaccine
US11707514B2 (en) 2016-09-02 2023-07-25 Sanofi Pasteur Inc. Neisseria meningitidis vaccine
CN120241991A (zh) * 2025-06-05 2025-07-04 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Also Published As

Publication number Publication date
US20130022633A1 (en) 2013-01-24
JP2016040302A (ja) 2016-03-24
JP2014503172A (ja) 2014-02-13
AU2010310985A1 (en) 2012-05-24
US20140348869A1 (en) 2014-11-27
AU2010310985B2 (en) 2014-11-06
MX2012004850A (es) 2012-05-22
EP2493499A1 (en) 2012-09-05
WO2011051893A1 (en) 2011-05-05
JP5960055B2 (ja) 2016-08-02
CA2779816A1 (en) 2011-05-05
BR112012010531A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
CN102917730A (zh) 修饰的脑膜炎球菌fHBP多肽
CN102596240B (zh) 包括脑膜炎球菌fHBP序列的杂交多肽
EP3263591B1 (en) Meningococcal fhbp polypeptides
CN102724988B (zh) 脑膜炎球菌fHBP多肽的表达
AU2016273825A1 (en) Modified meningococcal fHBP polypeptides
AU2015200160A1 (en) Modified meningococcal fHBP polypeptides
AU2014250679A1 (en) Meningococcal fHBP polypeptides
AU2013202472A1 (en) Hybrid polypeptides including meningococcal fHBP sequences
AU2013202581A1 (en) Expression of meningococcal fhbp polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130206

WD01 Invention patent application deemed withdrawn after publication